

Table S1. *BRCA1/2* pathogenic variants.

Patient (n)	Gene	Exon	Type	Nucleotide change	Amino Acid change	Designation
1	BRCA2	11	Frameshift	del†CA	p.Gln499Argfs*14	c.1496_1497del
2	BRCA1	24	Missense	T to C	p.Trp1837Arg	c.5509T>C
3	BRCA1	11	Splice	G to A	/	c.4096+1G>A
4	BRCA1	17	Frameshift	delCTAAT	p.Leu1679Tyrfs*2	c.5030_5034del
5	BRCA2	11	Nonsense	C to T	p.Gln1925*	c.5773C>T
6	BRCA1	17	Frameshift	delCTAAT	p.Leu1679Tyrfs*2	c.5030_5034del
7	BRCA2	21	Nonsense	C to T	p.Gln2894*	c.8680C>T
8	BRCA1	22	Nonsense	G to A	p.Trp1836*	c.5444G>A
9	BRCA2	19	Splice	G to T	/	c.8488-1G>T
10	BRCA1	11	Nonsense	G to T	p.Glu1001*	c.3001G>T
11	BRCA1	11	Frameshift	delCTCA	p.Ser282Tyrfs*15	c.843_846del
12	BRCA1	11	Frameshift	delA	p.Asn363Ilefs*11	c.1088delA
13	BRCA2	11	Frameshift	delTAACT	p.Asn2135Lysfs*3	c.6402_6406del
14	BRCA1	11	Frameshift	delGTCT	p.Ser1253Argfs*10	c.3756_3759del
15	BRCA2	11	Frameshift	delTAACT	p.Asn2135Lysfs*3	c.6402_6406del

Abbreviations: n, number; del, deletion.

Table S2. Adverse Events by BRCA status.*

Event	Grade 3/4 BRCA pathogenic variants (n = 15)	Grade 3/4 BRCA Wild-type (n = 54)	Grade 3/4 BRCA Untested (n = 15)
Hematologic event – n (%)			
Neutropenia	2 (13)	15 (28)	3 (20)
Anemia	0	1 (2)	0
Thrombocytopenia	0	2 (4)	0
Nonhematologic event – n (%)			
Fatigue	0	5 (9)	0
Elevation of AST/ALT	3 (20)	15 (28)	3 (20)
Nausea	0	1 (2)	0
Alopecia	0	2 (4)	1 (7)
Diarrhea	0	0	0
Constipation	0	1 (2)	0
Peripheral neuropathy	0	1 (2)	0
Rash	0	1 (2)	1 (7)
Vomiting	0	1 (2)	0
Oral mucositis	0	0	0

Abbreviations: n, number; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

*The safety analysis set included the 84 patients who received at least one dose of study drugs.